The body's oxygen-sensing machinery appears to play a previously unrecognized role in fighting respiratory viruses, potentially opening new therapeutic avenues for common infections that burden millions annually. This discovery challenges the conventional view that cellular oxygen responses primarily affect metabolism and tissue adaptation.
Researchers demonstrated that hypoxia-inducible factors (HIFs) - proteins that typically help cells survive low-oxygen conditions - actively suppress pneumovirus replication by amplifying innate immune detection systems. Using daprodustat, an FDA-approved medication that stabilizes HIFs, the team showed enhanced antiviral responses against respiratory syncytial virus and pneumonia virus in laboratory models. The HIF pathway appeared to boost the cellular sensors that recognize viral RNA, triggering stronger interferon production and limiting viral spread.
This finding connects two major biological systems in an unexpected way. HIFs are best known for their role in altitude adaptation, wound healing, and cancer progression, while pneumoviruses cause significant respiratory disease burden, particularly in children and elderly adults. The intersection suggests that therapeutic HIF activation could complement existing antiviral strategies, especially for populations most vulnerable to severe respiratory infections.
The research remains early-stage, conducted primarily in cell culture and animal models. Whether HIF enhancement provides meaningful clinical protection in humans requires extensive validation. The approach also carries theoretical risks, since prolonged HIF activation has been linked to tumor growth in some contexts. However, the concept of repurposing existing oxygen-sensing drugs for infectious disease represents a novel direction that could accelerate treatment development compared to designing entirely new antiviral compounds.